Brief: Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies
04/01/2018 22:43
Jan 4 (Reuters) - Helix Biopharma Corp HBP.TO :
* HELIX BIOPHARMA CORP. SIGNS BINDING LETTER OF INTENT FOR
DEVELOPMENT OF NEW CAR-T TECHNOLOGIES
* SAYS IMMEDIATE FOCUS WILL INVOLVE PRECLINICAL WORK IN
SUPPORT
OF A NEW IND APPLICATION OF A CAR-T FOR HEMATOLOGICAL
MALIGNANCIES
* SAYS FINALIZATION OF COLLABORATIVE BINDING LOI WITH
PROMAB
BIOTECHNOLOGIES TO DEVELOP CHIMERIC ANTIGEN RECEPTOR CAR-T FOR
HEMATOLOGICAL MALIGNANCES AND SOLID TUMOURS
* SAYS UNDER AGREEMENT,CO RETAINS EXCLUSIVE LICENSE FOR
COMMERCIALIZATION OF PRODUCT CANDIDATES DEVELOPED ALONE OR IN
COMBINATION WITH DOS47
Source text for Eikon: ID:nCCNccb4ja
Further company coverage: HBP.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020